echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bristol-Myers Squibb Innovative Oral Psoriasis Therapy Announces Phase 3 Clinical Results for the First Time

    Bristol-Myers Squibb Innovative Oral Psoriasis Therapy Announces Phase 3 Clinical Results for the First Time

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Bristol-Myers Squibb (BMS) announced the positive results of two phase 3 clinical trials of its potential "first-in-class" oral selective TYK2 inhibitor deucravacitinib in the treatment of patients with moderate to severe psoriasis.


    Psoriasis, also known as psoriasis, is a widespread chronic systemic immune-mediated disease that affects at least 100 million people worldwide.


    TYK2 is a member of the JAK family and is an intracellular signal kinase that mediates the signal transduction of IL-23, IL-12 and type I interferon (IFN).


    ▲Deucravacitinib has a unique mechanism of action (picture source: Bristol-Myers Squibb official website)

    Deucravacitinib developed by BMS is an oral selective TYK2 inhibitor.


    In two randomized, double-blind, placebo and oral active-controlled Phase 3 clinical trials, a total of more than 1,600 patients with moderate to severe psoriasis received deucravacitinib, PDE4 inhibitor apremilast, or placebo.


    Using PASI 75 (meaning a 75% improvement in the patient’s psoriasis area and severity index) as a measure, after 16 weeks of treatment, the proportion of patients treated with deucravacitinib that reached PASI 75 was 58.


    ▲Deucravacitinib significantly improved the proportion of patients reaching PASI 75 in two phase 3 clinical trials (picture source: reference [2])

    Using sPGA 0/1 (meaning that the patient’s skin symptoms are completely or almost completely cleared according to the doctor’s overall assessment) as a measure, after 16 weeks of treatment, the proportion of patients with deucravacitinib reaching this standard was 53.


    ▲Deucravacitinib significantly improved the proportion of patients reaching sPGA 0/1 in two phase 3 clinical trials (picture source: reference [2])

    In terms of safety, deucravacitinib also has a good performance.


    ▲Bristol-Myers Squibb will promote the clinical project of deucravacitinib in the treatment of various immune-mediated diseases (picture source: reference [2])

    "The findings of these two studies prove that deucravacitinib may become the preferred oral therapy for patients with psoriasis.


    Reference materials:

    [1] Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast).


    [2] AAD 2021 Investor Presentation.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.